ACSL4 and metabolic dysfunction-associated steatotic liver disease: Studies have highlighted the upregulation of hepatic ACSL4 in NAFLD patients, with ACSL4 suppression yielding beneficial effects on liver steatosis and fibrosis in preclinical models [19].